In a surprise move, the FDA has reversed its request for a new behavioural study of Epigenomics’ blood-based colorectal cancer (CRC) diagnostic test, Epi proColon. US marketing clearance and launch now look likely over the coming few months. With a current cash reach to H216, a cash call may now be deferred until after a possible US approval, and the consequent increased certainty may prove beneficial to current shareholders.
13 Jan 2016
Epi proColon gets FDA fillip
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Epi proColon gets FDA fillip
In a surprise move, the FDA has reversed its request for a new behavioural study of Epigenomics’ blood-based colorectal cancer (CRC) diagnostic test, Epi proColon. US marketing clearance and launch now look likely over the coming few months. With a current cash reach to H216, a cash call may now be deferred until after a possible US approval, and the consequent increased certainty may prove beneficial to current shareholders.